Back to Search
Start Over
Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients
- Source :
- Journal of Antimicrobial Chemotherapy, 71, 9, pp. 2379-85, Journal of Antimicrobial Chemotherapy, Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2016, 71 (9), pp.2379-85. ⟨10.1093/jac/dkw155⟩, Journal of Antimicrobial Chemotherapy, 2016, 71 (9), pp.2379-85. ⟨10.1093/jac/dkw155⟩, Journal of Antimicrobial Chemotherapy, 71, 2379-85
- Publication Year :
- 2016
- Publisher :
- Oxford University Press (OUP), 2016.
-
Abstract
- Contains fulltext : 171209.pdf (Publisher’s version ) (Closed access) Pneumocystis jirovecii can cause life-threatening pneumonia following treatment for haematological malignancies or after HSCT. The mortality rate of P. jirovecii pneumonia (PCP) in these patients is 30%-60%, especially after HSCT. The clinical presentation of PCP in haematology differs from that associated with HIV infection, with the disease being acute and more often severe, having a lower fungal burden and being more frequently linked to treatment with corticosteroids. Most cases occur in patients not receiving adequate prophylaxis. The development of new therapies, including targeted treatments and monoclonal antibodies in various haematological diseases, justifies constant vigilance in order to identify new at-risk populations and give prophylaxis accordingly. The fifth and sixth European Conferences on Infections in Leukaemia (ECIL-5 and ECIL-6) aimed to review risk factors for PCP in haematology patients and to establish evidence-based recommendations for PCP diagnosis, prophylaxis and treatment. This article focuses on the magnitude of the problem, the main differences in clinical presentation between haematology patients and other immunocompromised populations, especially HIV-infected patients, and the main risk factors.
- Subjects :
- 0301 basic medicine
Microbiology (medical)
medicine.medical_specialty
Antifungal Agents
[SDV]Life Sciences [q-bio]
medicine.medical_treatment
030106 microbiology
Disease
Hematopoietic stem cell transplantation
Pneumocystis carinii
Chemoprevention
[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Immunocompromised Host
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Pneumocystis jirovecii
Pharmacology (medical)
Intensive care medicine
Hematologic Neoplasms
Pneumonia, Pneumocystis
Stem Cell Transplantation
Transplant Recipients
Pharmacology
Infectious Diseases
Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]
Hematology
biology
Pneumocystis
business.industry
Mortality rate
Pneumonia
biology.organism_classification
medicine.disease
Penumocytis pneumonia
3. Good health
Leukemia
lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]
030220 oncology & carcinogenesis
immunocomrpomised host
Pnemocystis jirovecii
Stem cell
immunocomrpomised host, Penumocytis pneumonia, Pnemocystis jirovecii
business
Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Subjects
Details
- ISSN :
- 14602091 and 03057453
- Volume :
- 71
- Database :
- OpenAIRE
- Journal :
- Journal of Antimicrobial Chemotherapy
- Accession number :
- edsair.doi.dedup.....8ac568d85122259ea9c51c94880d867c